Artiva Biotherapeutics, Inc. ARTV
4.08 USD -0.14 (-3.37%)
Nov 10, 2026, 12:00 PM EST
4.06 Day range 4.22
2.96 52-week range 14.53
- YTD
- -4.95%
- 1 year
- +11.41%
News
benzinga.com Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
benzinga.com Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation Artiva Biotherapeutics ends its AlloNK program after fatal safety events, slashes 94% of its workforce, and weighs strategic liquidation.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Crude Oil Moves Lower; Corning Earnings Top Views U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.
benzinga.com Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4 Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation Clinical Development Discontinuation and Patient Follow-UpUpdated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion…
benzinga.com Artiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK Development Strategic Alternatives and Corporate RestructuringArtiva’s Board of Directors is evaluating internal options and potential strategic alternatives intended to maximize stockholder value. Leerink…
benzinga.com Artiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment Pause Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
benzinga.com Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.- benzinga.com Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients…
benzinga.com Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
benzinga.com Why Cracker Barrel Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket Cracker Barrel (CBRL) stock rises in pre-market trading after reporting better-than-expected Q3 results and raising FY26 sales guidance.
benzinga.com Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.- benzinga.com Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6 Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T…
- benzinga.com Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41 Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.
benzinga.com Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40 Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.
benzinga.com Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40 Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.- benzinga.com HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35 HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.
benzinga.com Artiva Biotherapeutics Stock Slides Despite Positive Trial Data Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Market-Moving News for May 8th RKLB: 8% | Rocket Lab shares are trading higher after the company reported better-than-expected Q1 sales results and issued Q2 sales guidance above estimates. The company announced it will acquire…
- benzinga.com Artiva Biotherapeutics Suspends Share Offering Under Sales Agreement With Leerink Partners On May 8, 2026, the Company delivered written notice to Leerink Partners LLC ("Leerink") that the Company has suspended and is not offering any shares of its common stock pursuant to the prospectus…
- benzinga.com Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.89) by 6.74 percent. This is a 14.46 percent decrease over…
benzinga.com Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting lower-than-expected earnings and sales.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.
- benzinga.com Artiva Biotherapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.45 percent. This is a 27.27 percent decrease over…
- benzinga.com Artiva Biotherapeutics Appoints Thad Huston CFO, Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating…
- benzinga.com Artiva Biotherapeutics To Highlight Cost-Effectiveness Of AlloNK In Community Rheumatology Practice And Continued Durability Of AlloNK In Non-Hodgkin Lymphoma At 2026 Tandem Meetings Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Crude Oil Falls Over 1%; US Homebuilder Sentiment Edges Higher In December - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com US Stocks Mixed; NY Manufacturing Activity Dips In December - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $15 HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $12 to $15.
- benzinga.com Artiva Biotherapeutics Showcases AlloNK As First Off-The-Shelf NK Cell Therapy Demonstrating Deep B-Cell Depletion With Favorable Tolerability Profile 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoffAll patients received AlloNK as outpatients, and the majority were…
benzinga.com Artiva Biotherapeutics To Host Event For Discussing Safety, Translational Data For AlloNK In Combination With Anti-cd20 Antibodies Across Autoimmune Diseases Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune…
benzinga.com 4 Biotech Stocks Lifting Off As Momentum Builds Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Is Artiva Up Today? Shares of Artiva Biotherapeutics, Inc. are rising Friday after the San Diego-based biotech company shared a milestone regulatory update.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings 
benzinga.com Dow Gains Over 100 Points; American Express Increases 2025 Forecast